Vestal Point Capital’s Dianthus Therapeutics DNTH Stock Holding History

Vestal Point Capital’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,180,000	Closed	-$46.4M	–	90
2025 Q3	$46.4M	Sell	1,180,000 -2,020,000	-63%	-$51.6M	2.1%	15
2025 Q2	$59.6M	Buy	3,200,000 +1,499,931	+88%	+$28.1M	3.14%	8
2025 Q1	$30.8M	Buy	1,700,069 +625,069	+58%	+$13.8M	2.2%	16
2024 Q4	$23.4M	Buy	1,075,000 +680,000	+172%	+$17.5M	1.39%	27
2024 Q3	$10.8M	Sell	395,000 -205,000	-34%	-$5.71M	0.82%	31
2024 Q2	$15.5M	Buy	600,000 +145,000	+32%	+$3.49M	1.16%	28
2024 Q1	$13.7M	Buy	455,000 +320,000	+237%	+$6.96M	1.13%	23
2023 Q4	$1.4M	Buy	+135,000	New	+$1.49M	0.15%	38

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vestal Point Capital's DNTH Position: Q4 2025 in Review

Vestal Point Capital sold out of Dianthus Therapeutics (DNTH) in Q4 2025, closing a stake of 1,180,000 shares — an estimated $46.4M sold.

Vestal Point Capital first reported a position in DNTH in Q4 2023 and held it in 8 quarters. The position peaked at $59.6M in Q2 2025. 165 funds tracked by Wall St. Rank hold DNTH as of Q4 2025.

Vestal Point Capital reported no remaining Dianthus Therapeutics position as of Q4 2025 after selling out during the quarter.
Vestal Point Capital sold 1,180,000 Dianthus Therapeutics shares in Q4 2025, an estimated $46.4M.
Vestal Point Capital first reported a position in Dianthus Therapeutics in Q4 2023 and held it in 8 quarters.
Vestal Point Capital's Dianthus Therapeutics position peaked at $59.6M in Q2 2025.
165 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2025.

Based on Vestal Point Capital's 13F filing for Q4 2025, filed 17 Feb 2026.